- Q4 2023 InflaRx NV Earnings Call TranscriptMar 21, 2024€1.43 (-9.51%)Earnings
- InflaRx NV Conference Call TranscriptJan 04, 2024
- InflaRx NV at HC Wainwright Investment Conference - New York TranscriptSep 11, 2023
- InflaRx NV Corporate Call TranscriptSep 11, 2023
- InflaRx NV PANAMO Ph3 Results Call TranscriptMar 31, 2022
- InflaRx NV Virtual R&D Event TranscriptFeb 03, 2022
- InflaRx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 13, 2022
- Inflarx NV at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 10, 2021
- Inflarx NV Pyoderma Gangrenosum Cohort Three Top-Line Results Conference Call TranscriptOct 27, 2021
- Inflarx NV at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 23, 2021
- Inflarx NV at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Inflarx NV at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Inflarx NV Earnings Call TranscriptNov 07, 2019€2.44 (+1.67%)Earnings
- InflaRx N.V. - Special Call TranscriptJul 19, 2019
InflaRx NV at HC Wainwright Investment Conference - New York Transcript
Good day, everyone, and thank you for joining the H.C. Wainwright 25th Annual Global Investment Conference. My name is Steve Bersey. I'm an equity research associate here at H.C. Wainwright and it's my pleasure to introduce Niels C. Riedemann, CEO of InflaRx. So I'll turn it over to Neils.
Thank you so much, also for having us here today. We are happy to present. I'm here with our team Dr. Camilla Chong, our Chief Medical Officer, and Dr. Thomas Taapken, our CFO. So happy to go into the presentation right away. We had also some data released today, which I will spend a bit time on as well. So we're excited about that. But before I start, please take note of our corporate disclaimer, I'll be making forward-looking statements and also comparisons to published data of other molecules. So please take note of the disclaimer.
So when looking at our pipeline we are really in the terminal complement C5a, C5aR are spaced now with two very
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)